CatalYm is a biopharmaceutical company developing novel cancer immunotherapies targeting Growth-and-Differentiation Factor 15 (GDF-15). Apart from its established role in cachexia, GDF-15 has been associated with immunosuppression in tissues and tumors and a rapidly growing body of literature supports the concept that GDF-15 is a major T cell repellent. CatalYm aims to neutralize GDF-15 to turn “cold” tumors “hot” and thereby substantially improving the efficacy of established immunotherapy such as anti-PD1/-PD-L1 checkpoint inhibitors. The company’s lead product candidate CTL-002, a neutralizing GDF-15 antibody, is set to enter clinical development in H2 2020.
The Company was founded with initial investments from Forbion and BGV in 2016 as a spin-off from the Julius-Maximilians-University of Würzburg based on the innovative research work of Prof. Dr. Joerg Wischhusen. CatalYm is led by a seasoned senior executive team with substantial IO drug development as well as deal making experience and backed by international venture capital investors.
CatalYm also received financial support from the EIF via the EIB-EIF Co-investment Facility, backed by the European Union through the European Fund for Strategic Investments (EFSI).
- Founding: 2016
- Focus : Manufacturer
- Employees: 11-50
- Industry : Biotechnology, Pharma
Products from CatalYm
News about CatalYm
24-Nov-2022 | Finances
CatalYm Closes EUR 50 Million Series C Financing
CatalYm announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon ...
06-May-2021 | People
CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Office
CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, announced the appointment of Dr. Phil L’Huillier as Chief Executive ...